Get started
Author

Ian Tracy

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
2010 · T Zenz, D Vollmer, et al. · Leukemia · 181
Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response
2025 · Benjamin H. Jenkins, Ian Tracy, et al. · Molecular Cancer · 105
PDF
A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
2008 · O G Best, A C Gardiner, et al. · Leukemia · 99
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
2017 · Lekh N. Dahal, Lang Dou, et al. · Cancer Research · 86
Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL
2016 · Annalisa D’Avola, Samantha Drennan, et al. · Blood · 63
PDF
Defining the prognosis of early stage chronic lymphocytic leukaemia patients
2011 · Chris Pepper, Aneela Majid, et al. · British Journal of Haematology · 55
PDF
Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
2018 · Samantha Drennan, Giorgia Chiodin, et al. · Clinical Cancer Research · 29
PDF
The frequency of TP 53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors
2014 · Jitka Malcikova, Evangelia Stalika, et al. · British Journal of Haematology · 22
PDF
A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia
2011 · Anne Gardiner, Helen Parker, et al. · Leukemia Research · 12
Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma
2024 · Nicola J Smith, Ian Reddin, et al. · The EMBO Journal · 10
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
2022 · Giorgia Chiodin, Samantha Drennan, et al. · Blood Advances · 9
Targeting EZH2 for the treatment of soft tissue sarcomas
2021 · Magdalena Karolak, Ian Tracy, et al. · Journal of Cancer Metastasis and Treatment · 9
PDF
Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells
2023 · Eleanor O’Brien, Carmen Tse, et al. · Clinical Epigenetics · 8
PDF
Type C TP 53‐ CDKN 1A pathway dysfunction occurs independently of CDKN 1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP 53 abnormalities
2016 · Ian Tracy, William Tapper, et al. · British Journal of Haematology · 6
PDF
High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients
2019 · Giorgia Chiodin, David Dutton, et al. · Blood · 5
TP53 Abnormalities in Chronic Lymphocytic Leukemia Exhibit a Disease Specific Profile: Meta-Analysis of 270 Mutations.
2008 · Thorsten Zenz, Jana Smadova, et al. · Blood · 4
Supplemetary data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
2023 · Lekh N. Dahal, Lang Dou, et al.
Data from STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
2023 · Lekh N. Dahal, Lang Dou, et al.
Supplementary Tables and Figures from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
2023 · Samantha Drennan, Giorgia Chiodin, et al.
Data from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
2023 · Samantha Drennan, Giorgia Chiodin, et al.
Data from Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients
2023 · Samantha Drennan, Giorgia Chiodin, et al.
The detection and clinical significance of TP53 dysfunction in chronic lymphocytic leukaemia.
2017 · Ian Tracy · Bournemouth University Research Online (Bournemouth University)
PDF
Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia
2014 · Samantha J Drennan, Annalisa D'Avola, et al. · Blood
Distinct frequency and profiles of TP53 gene mutations in CLLsubgroups with distinct antigen receptors: Evidence forantigen-driven selection of genomci aberrations.
2013 · Jitka Malčíková, Evangelia Stalika, et al.
4.21 Functional Categorisation of Tumour Cell p53/p21 Responses to Etoposide and Nutlin3a Exposure Correlates with Bi-allelic ATM Lesions and Mono- or Bi-allelic Lesions of TP53 in Chronic Lymphocytic Leukaemia
2011 · Ian Tracy, Giles Best, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 39
Citation count: 703
H-index: 10
I10-index: 10
Year
Topic
Type